Gilead Sciences (GILD) Asset Writedowns and Impairment (2016 - 2026)

Gilead Sciences (GILD) has reported Asset Writedowns and Impairment for 6 consecutive years, with $1.8 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Asset Writedowns and Impairment rose 821.05% year-over-year to $1.8 billion; the trailing twelve-month figure through Jun 2026 stood at $2.3 billion (up 17.59% YoY), and the FY2025 full-year result was $590.0 million, down 85.95% from the prior year.
• Asset Writedowns and Impairment improved to $1.8 billion in Q2 2026 per GILD's latest filing, from $400.0 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $2.7 billion in Q1 2022 and bottomed at $50.0 million in Q4 2023.
• Historically, Asset Writedowns and Impairment has averaged $1.3 billion across 5 years, with a median of $1.8 billion in 2026.
• The widest YoY moves for Asset Writedowns and Impairment: up 821.05% in 2026, down 821.05% in 2026.
• Over 5 years, Asset Writedowns and Impairment stood at $2.7 billion in 2022, then plunged by 98.15% to $50.0 million in 2023, then surged by 3500.0% to $1.8 billion in 2024, then sank by 77.78% to $400.0 million in 2025, then soared by 337.5% to $1.8 billion in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $1.8 billion, $400.0 million, and $190.0 million for Q2 2026, Q4 2025, and Q2 2025 respectively.